Optimize Guideline-Directed Medical Therapy and Discharge Without Further Testing
In a patient with known CAD who has moderate stenosis (50-69%) with a negative FFR-CT, the next step is to optimize guideline-directed medical therapy (GDMT) and discharge the patient without additional invasive testing. 1, 2, 1
Rationale Based on Current Guidelines
The 2021 AHA/ACC Chest Pain Guidelines provide clear algorithmic guidance for this exact scenario. When FFR-CT is negative (≥0.80) in the setting of moderate stenosis, this indicates the lesion is not hemodynamically significant and does not cause flow-limiting ischemia 1, 2.
Key Management Steps:
1. Discharge with Optimized Medical Therapy
- The negative FFR-CT effectively rules out vessel-specific ischemia requiring revascularization
- Focus on aggressive risk factor modification and preventive pharmacotherapy 3, 4, 3
- Optimize anti-anginal medications if symptomatic (beta-blockers, calcium channel blockers, nitrates)
2. Guideline-Directed Medical Therapy Components:
- Antiplatelet therapy: Aspirin ± P2Y12 inhibitor based on individual risk
- Statin therapy: High-intensity statin for aggressive LDL reduction
- Blood pressure control: Target <130/80 mmHg
- Diabetes management if applicable
- Lifestyle modifications: Smoking cessation, exercise, Mediterranean diet
3. The Mixed-Density Plaque Finding: While the presence of mixed plaque (containing both calcified and non-calcified components) indicates atherosclerotic disease burden, the negative FFR-CT is the decisive factor for management 3. The plaque characterization informs the aggressiveness of preventive therapy but does not change the decision against revascularization when FFR-CT is negative.
When to Consider Additional Testing
Do NOT pursue further testing unless:
- Patient develops frequent or persistent angina despite optimal medical therapy 3, 4
- New symptoms emerge suggesting disease progression
- Very high-grade stenosis (>90%) is present on anatomic imaging 3
- High-risk features develop (left main disease, three-vessel disease) 1, 2
Evidence Strength and Nuances
The 2021 AHA/ACC guidelines (Class 2a, Level B-NR) specifically state that FFR-CT is reasonable for diagnosis of vessel-specific ischemia and to guide decision-making regarding coronary revascularization 1, 2. Multiple registries, including the ADVANCE registry with 5,083 patients, demonstrated no MACE at 90 days for patients with negative FFR-CT who were managed conservatively 5.
The CAD-RADS 2.0 classification system (2022) reinforces this approach: moderate stenosis (CAD-RADS 3) with negative ischemia testing (I-) should be managed with GDMT and discharge 3, 4, 3.
Common Pitfall to Avoid:
Do not reflexively pursue invasive coronary angiography based solely on the anatomic finding of moderate stenosis. The "oculostenotic reflex" (revascularizing based on stenosis severity alone) has not proven beneficial in stable patients 6. The negative FFR-CT provides the functional assessment needed to safely defer invasive procedures.
The benefit of revascularization is confined to patients with frequent symptoms despite optimal medical therapy 3, 4. Without ongoing symptoms or positive ischemia testing, revascularization does not reduce mortality or myocardial infarction risk 7.